Economides Vassiliki, the Chief Financial Officer of Adial Pharmaceuticals, Inc., has reported stock options in a recent SEC filing. This filing, dated October 30, 2026, provides insight into the executive compensation structure at Adial Pharmaceuticals and highlights the role of key personnel in the company’s strategic direction.

Adial Pharmaceuticals, based in Charlottesville, Virginia, is engaged in the pharmaceutical preparations sector. The company has been active in filing various reports with the SEC, including recent filings that detail the ownership and compensation of its executives. The latest filing indicates that Economides holds stock options that may significantly influence their future contributions to the company.

According to the filing, Economides has been granted stock options to purchase 307,814 shares of common stock at an exercise price of $5.76. These options are set to vest over a period of time, with 25% vesting on the first anniversary of the grant date, which is August 19, 2026, and the remaining shares vesting in monthly installments thereafter. This structure is designed to retain key executives and align their interests with those of shareholders.

The filing also notes that Economides does not currently own any securities outright, indicating that their compensation is primarily tied to the performance of the stock options. This approach is common in the industry, as companies seek to incentivize executives to drive company growth and enhance shareholder value.

The implications of this filing extend beyond just Adial Pharmaceuticals. It reflects broader trends in the pharmaceutical preparations industry, where competitive compensation packages are essential for attracting and retaining top talent. As companies navigate the complexities of drug development and regulatory challenges, having experienced leadership can be a significant asset.

While the filing does not specify what actions will follow, it underscores the importance of executive roles in shaping the future of Adial Pharmaceuticals. The company continues to position itself within the pharmaceutical sector, and the retention of key executives like Economides is crucial for its ongoing success.

Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this matter. However, stakeholders will likely keep a close watch on how these developments impact Adial Pharmaceuticals and its strategic initiatives moving forward.